ACADIA PHARMACEUTICALS INC. Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
ACADIA PHARMACEUTICALS INC. (ACAD) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $1.54 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $1.54M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $636.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $57.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $110.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2026-06-30 | $1.54M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $636.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $57.00K 10-Q · filed 2026-08-05 |
| 2025-09-30 | $110.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $117.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $59.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $108.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $28.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $345.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $242.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $140.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $357.00K 10-Q · filed 2023-11-03 |
| 2023-06-30 | $557.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $261.00K 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.04M 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.42M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $883.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $626.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $213.00K 10-K · filed 2023-02-28 |
| 2020-12-31 | $43.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |